Overview

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Status:
COMPLETED

Trial end date:
2024-03-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn what happens to MK-8591A in a person's body over time. Researchers will compare what happens to MK-8591A in the body when it is given with and without food.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

doravirine
islatravir